Characterization of the activities of actin-affecting drugs on tumor cell migration.

Metastases kill 90% of cancer patients. It is thus a major challenge in cancer therapy to inhibit the spreading of tumor cells from primary tumor sites to those particular organs where metastases are likely to occur. Whereas the actin cytoskeleton is a key component involved in cell migration, agents targeting actin dynamics have been relatively poorly investigated. Consequently, valuable in vitro pharmacological tools are needed to selectively identify this type of agent. In response to the absence of any standardized process, the present work aims to develop a multi-assay strategy for screening actin-affecting drugs with anti-migratory potentials. To validate our approach, we used two cancer cell lines (MCF7 and A549) and three actin-affecting drugs (cytochalasin D, latrunculin A, and jasplakinolide). We quantified the effects of these drugs on the kinetics of actin polymerization in tubes (by means of spectrofluorimetry) and on the dynamics of actin cytoskeletons within whole cells (by means of fluorescence microscopy). Using quantitative videomicroscopy, we investigated the actual effects of the drugs on cell motility. Finally, the combined drug effects on cell motility and cell growth were evaluated by means of a scratch-wound assay. While our results showed concordant drug-induced effects on actin polymerization occurring in vitro in test tubes and within whole cells, the whole cell assay appeared more sensitive than the tube assay. The inhibition of actin polymerization induced by cytochalasin D was paralleled by a decrease in cell motility for both cell types. In the case of jasplakinolide, which induces actin polymerization, while it significantly enhanced the locomotion of the A549 cells, it significantly inhibited that of the MCF-7 ones. All these effects were confirmed by means of the scratch-wound assay except of the jasplakinolide-induced effects on MCF-7 cell motility. These later seemed compensated by an additional effect occurring during wound recolonization (possibly acting on the cell growth features). In conclusion, the use of multi-assays with different levels of sophistication and biological relevance is recommended in the screening of new actin-affecting drugs with potentially anti-migratory effects.

[1]  Carlos López-Otín,et al.  Strategies for MMP inhibition in cancer: innovations for the post-trial era , 2002, Nature Reviews Cancer.

[2]  Kerstin Lang,et al.  Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. , 2004, The Lancet. Oncology.

[3]  S. Zucker,et al.  Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment , 2000, Oncogene.

[4]  J. Rao,et al.  Microfilament actin remodeling as a potential target for cancer drug development. , 2004, Current cancer drug targets.

[5]  R. Kiss,et al.  Characterization of Gastrin-Induced Proangiogenic Effects In vivo in Orthotopic U373 Experimental Human Glioblastomas and In vitro in Human Umbilical Vein Endothelial Cells , 2004, Clinical Cancer Research.

[6]  J M Zahm,et al.  Cell migration and proliferation during the in vitro wound repair of the respiratory epithelium. , 1997, Cell motility and the cytoskeleton.

[7]  H. Bult,et al.  Effects of local cytochalasin D delivery on smooth muscle cell migration and on collar‐induced intimal hyperplasia in the rabbit carotid artery , 2001, British journal of pharmacology.

[8]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[9]  R. Kiss,et al.  Influence of gastrin on human astrocytic tumor cell proliferation. , 1996, Journal of the National Cancer Institute.

[10]  T. Sawyer.  Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors , 2004, Expert opinion on investigational drugs.

[11]  H. Verschueren,et al.  Effects of Clostridium botulinum C2 toxin and cytochalasin D on in vitro invasiveness, motility and F-actin content of a murine T-lymphoma cell line. , 1995, European journal of cell biology.

[12]  J. Harmon,et al.  Actin disruption inhibits bombesin stimulation of focal adhesion kinase (pp125FAK) in prostate carcinoma. , 1996, Journal of Surgical Research.

[13]  C. Waterman-Storer,et al.  Conserved microtubule–actin interactions in cell movement and morphogenesis , 2003, Nature Cell Biology.

[14]  M. Sporn.  The war on cancer , 1996, The Lancet.

[15]  D A Lauffenburger,et al.  Tumor invasion as dysregulated cell motility. , 2001, Seminars in cancer biology.

[16]  E. Sausville,et al.  Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin. , 1994, The Journal of biological chemistry.

[17]  C. McCulloch,et al.  Simultaneous localization and quantification of relative G and F actin content: optimization of fluorescence labeling methods. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[18]  L. Cramer.  Role of actin-filament disassembly in lamellipodium protrusion in motile cells revealed using the drug jasplakinolide , 1999, Current Biology.

[19]  E. Friederich,et al.  The actin cytoskeleton as a therapeutic target: state of the art and future directions. , 2003, Progress in cell cycle research.

[20]  Robert Kiss,et al.  In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton. , 2002, International journal of oncology.

[21]  M. Jordan,et al.  Microtubules and actin filaments: dynamic targets for cancer chemotherapy. , 1998, Current opinion in cell biology.

[22]  A. Raz,et al.  Autocrine motility factor signaling induces tumor apoptotic resistance by regulations Apaf‐1 and Caspase‐9 apoptosome expression , 2003, International journal of cancer.

[23]  Isabelle Camby,et al.  A model‐based approach for automated in vitro cell tracking and chemotaxis analyses , 2004, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[24]  M. Grever,et al.  Jasplakinolide's inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeleton. , 1995, Journal of the National Cancer Institute.

[25]  Y. Endo,et al.  The motility of hepatic Ito cells can be acquired by their myofibroblastic transformation. , 2002, Archives of histology and cytology.

[26]  G. Naumov,et al.  Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. , 2002, Cancer research.

[27]  I. Spector,et al.  Effects of Jasplakinolide on the Kinetics of Actin Polymerization , 2000, The Journal of Biological Chemistry.

[28]  I. Spector,et al.  Latrunculins--novel marine macrolides that disrupt microfilament organization and affect cell growth: I. Comparison with cytochalasin D. , 1989, Cell motility and the cytoskeleton.

[29]  J. Cooper,et al.  Effects of cytochalasin and phalloidin on actin , 1987, The Journal of cell biology.

[30]  T. Kouyama,et al.  Fluorimetry study of N-(1-pyrenyl)iodoacetamide-labelled F-actin. Local structural change of actin protomer both on polymerization and on binding of heavy meromyosin. , 2005, European journal of biochemistry.

[31]  D. Peeper,et al.  Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB , 2004, Nature.

[32]  R. Kiss,et al.  In vitro and in vivo pharmacological characterizations of the antitumor properties of two new olivacine derivatives, S16020-2 and S30972-1. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  R. Kiss,et al.  Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Gabriel Fenteany,et al.  Small-molecule inhibitors of actin dynamics and cell motility. , 2003, Current topics in medicinal chemistry.

[35]  L. Liotta,et al.  Cytoskeletal agents inhibit motility and adherence of human tumor cells. , 1993, Kidney international.

[36]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[37]  Isabelle Camby,et al.  S100A2, a Putative Tumor Suppressor Gene, Regulates In Vitro Squamous Cell Carcinoma Migration , 2001, Laboratory Investigation.

[38]  P. Friedl,et al.  Tumour-cell invasion and migration: diversity and escape mechanisms , 2003, Nature Reviews Cancer.

[39]  S. Brenner,et al.  Inhibition of actin polymerization by latrunculin A , 1987, FEBS letters.

[40]  R. Kiss,et al.  Galectin‐1 Modulates Human Glioblastoma Cell Migration into the Brain Through Modifications to the Actin Cytoskeleton and Levels of Expression of Small GTPases , 2002, Journal of neuropathology and experimental neurology.

[41]  C Decaestecker,et al.  Gastrin inhibits motility, decreases cell death levels and increases proliferation in human glioblastoma cell lines. , 1998, Journal of neurobiology.

[42]  G. Tucker.  Alpha v integrin inhibitors and cancer therapy. , 2003, Current opinion in investigational drugs.

[43]  S. Evans.  The Origin of Civilisation and the Primitive Condition of Man : Mental and Social Condition of Savages , 1871, Nature.

[44]  S. Étienne-Manneville.  Actin and Microtubules in Cell Motility: Which One is in Control? , 2004, Traffic.

[45]  H. Bielka,et al.  Defined sequence segments of the small heat shock proteins HSP25 and alphaB-crystallin inhibit actin polymerization. , 2001, European journal of biochemistry.

[46]  A. Gotlieb,et al.  In vitro endothelial wound repair. Interaction of cell migration and proliferation. , 1990, Arteriosclerosis.

[47]  F. Braet,et al.  New anti‐actin drugs in the study of the organization and function of the actin cytoskeleton , 1999, Microscopy research and technique.

[48]  M. Westphal,et al.  Cost of migration: invasion of malignant gliomas and implications for treatment. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Philippe Van Ham,et al.  Tracking of migrating cells under phase-contrast video microscopy with combined mean-shift processes , 2005, IEEE Transactions on Medical Imaging.